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Background/aim: Vascular risk factors play an important role in the progression of Alzheimer disease (AD). Mean platelet volume
(MPV) is a determinant of platelet functionality and increased MPV is associated with an increased risk of vascular inflammation. Here
we aimed to examine whether MPV could be used as a marker of vascular damage in AD and to discuss the relation between MPV and
other vascular risk factors.
Materials and methods: A total of 109 outpatients with AD and 81 healthy controls were included in this study. Diagnosis of AD
was made according to defined criteria. The Turkish version of the Mini Mental State Examination (MMSE) was used for cognitive
assessment. According to the test results, patients were divided into 2 subgroups, mild (MMSE ≥ 18) and moderate (MMSE < 18), and
their MPV levels were compared.
Results: MPV levels were higher in the AD group. There was no statistically significant difference between the moderate group and the
mild group according to MPV values.
Conclusion: Increased MPV in patients with AD may point to platelet dysfunction. MPV is an indicator of increased in vivo platelet
activation. Hence, platelets could be the link between vascular risk factors and AD. The assessment of MPV in patients with AD may
help identify the patients that could benefit from additional antiplatelet therapy.
Key words: Alzheimer disease, dementia, cognitive decline, mean platelet volume, platelet activation, vascular risk factors

1. Introduction
Alzheimer disease (AD) is the most common form of
dementia and is characterized by progressive cognitive
decline. Multiple risk factors, including hypertension,
diabetes mellitus, high serum homocysteine, atrial
fibrillation, atherosclerosis, high serum cholesterol, and
thrombogenic factors, are described for the pathogenesis
of AD. Several studies have shown that vascular risk
factors, atherosclerosis, and increased platelet activity play
an important role in the progression of dementia in AD. In
addition, AD and vascular dementia share many similar
risk factors and cannot be distinguished clinically. This
situation may support the role of vascular pathogenesis in
AD (1–3).
AD is characterized by the abnormal progressive
accumulation of amyloid-β (Aβ) in the brain’s parenchyma
and microvascular areas. Amyloid plaques consist of
insoluble deposits of Aβ, which originate from the amyloid
precursor protein (APP). This protein is expressed in the
* Correspondence: erabiakoc@yahoo.com
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central nervous system. In a healthy brain, these protein
fragments are broken down and eliminated. In patients
with AD, these fragments accumulate as insoluble plaques.
Several peripheral tissues produce APP normally. Platelets
are an important source of APP in the blood and involve
similar concentrations of APP isoforms as are found in the
brain (4,5). Many studies have shown that APP and Aβ
are stored in platelets and released into circulation with
platelet activation (2).
Mean platelet volume (MPV), the average size of
platelets in blood, is obtained from a routine blood count.
Therefore, MPV measurement is an easily applicable and
low-cost method for the assessment of platelet activity.
MPV is positively correlated with increased in vivo platelet
activity (6–10). MPV increases in vascular disease and in
the presence of risk factors (e.g., hypertension, diabetes
mellitus, hyperlipidemia) for vascular diseases (6–11).
Increased MPV values were reported in cardiovascular
disease and thromboembolic disorders (12). In addition,
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MPV was measured in acute ischemic stroke patients
and was found to be associated with prognosis (13–15).
Increased platelet activity and atherosclerosis contribute
to the progression of dementia in AD (1). Many significant
changes in levels and enzymatic activities of platelets in
AD have been demonstrated in several studies. Mediators
secreted by platelets contribute to the vascular events that
result in vascular inflammation and atherosclerosis (16).
In this study, we aimed to examine whether there is a
difference in the MPV level in patients with AD compared
to healthy controls and to discuss the relation between
MPV and other vascular risk factors.
2. Materials and methods
2.1. Study population and procedures
Patients diagnosed with AD were collected consecutively
from January 2009 until July 2012 in the Department of
Neurology at University Hospital. Data were obtained
by clinical interview, laboratory exams, physical and
neurological examination, and computed tomography
or magnetic resonance imaging. One hundred and nine
patients met the established diagnostic criteria of probable
AD (17,18). The Turkish version of the Mini Mental State
Examination (MMSE) was used to screen for cognitive
impairment (19,20). The MMSE is also used to follow
the course of cognitive change in an individual over time,
so it is an effective tool for the evaluation of response
to treatment. The maximum score is 30, and while high
points can never fully rule out dementia, higher scores
indicate better cognitive performance.
Patients with AD were divided into 2 subgroups for
mild (MMSE ≥ 18 points, 78 patients) and moderate
(MMSE < 18 points, 31 patients) cognitive impairment.
The control group consisted of 81 subjects, matched for
age and sex, without dementia, stroke, or hematologic
disease (21).
Laboratory exams included complete blood count,
chemical proﬁle, thyroid function test, and vitamin B12.
Participants who were active smokers or heavy drinkers,
who had cancer or abnormal liver or thyroid function
tests, or who were receiving antiplatelet or anticoagulant
therapy were excluded. The study protocol was approved
by the Ethics Committee of Fatih University. The aims
and procedures of the investigation were explained and a
consent form was provided by all participants. For patients
who were incapable of providing informed consent on
their own behalf, consent was obtained from relatives.
2.2. Biochemical and complete blood count analysis
After 12 h of fasting, blood samples were obtained in the
early morning (between 0900 and 1000 hours), and the
samples were analyzed at 1300 hours. Ten milliliters of
blood was drawn from the antecubital vein. The first 3 mL
of blood was used for the complete blood count and was

drawn into a vacutainer tube containing 0.04 mL of 7.5%
K3 salt of ethylenediaminetetraacetic acid. The remaining
7 mL of blood was drawn into a vacutainer tube without
anticoagulant and was left for 20 min before centrifugation.
Blood tubes were centrifuged for 10 min at 1500 × g and
were processed within 30 min. Complete blood counts
were done with a CELL-DYN 3700 SL analyzer (Abbott
Diagnostics, Chicago, IL, USA). Serum concentrations of
cholesterol, triglycerides, high-density lipoprotein (HDL)
cholesterol, and glucose were evaluated by the enzymatic
dry chemistry method using a Reflotron apparatus.
Low-density lipoprotein (LDL) cholesterol values were
evaluated according to the Friedewald formula. Serum
concentrations of free triiodothyronine (FT3), free
thyroxine (FT4), thyroid-stimulating hormone (TSH), and
vitamin B12 were measured by chemiluminescent assay
using a Roche Elecsys 2010 analyzer (Cobas, Mannheim,
Germany) with original kits.
2.3. Statistical analyses
Statistical analyses were performed using SPSS 15. The
variables were investigated using visual (histograms,
probability plots) and analytical methods (Kolmogorov–
Smirnov/Shapiro–Wilk test) to determine whether or
not they were normally distributed. Descriptive analyses
were presented using means and standard deviations for
normally distributed variables. Descriptive analyses were
presented using medians and interquartile ranges for the
nonnormally distributed variables and frequencies and
percentages for the ordinal variables. The Student t-test was
used to compare normally distributed variables between
the AD and control groups. The Mann–Whitney U test
was used to compare nonnormally distributed variables
between the AD and control groups. The chi-square test
was used to compare the proportions of patients with
diabetes and hypertension in the groups. P < 0.05 was
considered to show a statistically significant result.
3. Results
One hundred and nine patients diagnosed with AD and
81 healthy controls, making a total of 190 individuals,
were included in this study. Seventy patients (64.2%)
were female and 39 (35.8%) were male in the Alzheimer’s
group, while in the control group 56 (69.1%) were female
and 25 (30.9%) were male. Demographic and clinical
characteristics of individuals participating in the study are
shown in Table 1.
The average MPV was 8.54 ± 1.07 fL in the AD
group and 7.86 ± 0.74 fL in the control group. The mean
difference of 0.68 fL (confidence interval: 0.42–0.95)
that was calculated according to the control group was
statistically significant. MPV was significantly different
between the AD and control groups (P < 0.001) (Figure 1).
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Table 1. Demographic and clinical characteristics of patients.
Demographic and clinical characteristics

Group

Mean ± SD

Min–max

Alzheimer

76.74 ± 8.99

49–96

Control

75.32 ± 8.42

56–92

Duration of disease (years)

Alzheimer

2.65 ± 2.07

0–12

MMSE score

Alzheimer

19.27 ± 4.87

5–29

Age (years)

o102
12.0
o51
o

151
o

MPV

10.0

8.0

6.0
Alzheimer

Group

Control

Figure 1. Comparison of intergroup MPV values by box plot
chart.

The blood results are shown in Tables 2 and 3. The
average platelet count was 229.05 ± 61.789/mm3 in the
AD group and 263.10 ± 65.239/mm3 in the control group.
Platelet count was significantly different between the AD
and control groups (P < 0.001) (Figure 2).

The average hematocrit value was 40.33 ± 4.07% in the
AD group and 41.75 ± 3.76% in the control group. The
mean difference of 1.42 (confidence interval: –2.56 to –0.3)
that was calculated according to the control group was
statistically significant. Hematocrit value was significantly
different between the AD and control groups (P < 0.05).
The median hemoglobin level was 13.60 g/dL
(interquartile range: 2) in the AD group and 14.00 g/dL
(interquartile range: 1) in the control group. The 0.40 g/dL
difference was statistically significant. Hemoglobin value
was significantly different between the AD and control
groups (P < 0.05).
The mean total cholesterol value showing the lipid
profile was 197.71 ± 42.22 mg/dL in the AD group and
212.60 ± 37.49 mg/dL in the control group. The mean
difference of 14.90 mg/dL (confidence interval: –26.35 to
–3.44) that was calculated according to the control group
was statistically significant. Total cholesterol value was
significantly different between the AD and control groups
(P = 0.001).
The median triglyceride level was 114.00 mg/dL
(interquartile range: 69) in the AD group and 133.00 mg/
dL (interquartile range: 1) in the control group. The 19 mg/

Table 2. The blood results of patients.

Platelet count (×103/mm3)
MPV (fL)
Hematocrit (%)
Total cholesterol (mg/dL)
LDL (mg/dL)
Student t-test.
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Group

Mean ± SD

Alzheimer

229.05 ± 61.789

Control

263.10 ± 65.239

Alzheimer

8.54 ± 1.07

Control

7.86 ± 0.74

Alzheimer

40.33 ± 4.07

Control

41.75 ± 3.76

Alzheimer

197.71 ± 42.22

Control

212.60 ± 37.49

Alzheimer

118.49 ± 38.56

Control

127.75 ± 35.53

*: P < 0.01, µ: P < 0.05

t

P

–3.66

0.000*

4.94

0.000*

-2.43

0.016µ

–2.52

0.013µ

–1.69

0.092
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Table 3. Further blood results of patients.

Hb (g/dL)
Triglyceride (mg/dL)
VLDL (mg/dL)
HDL (mg/dL)

Group

Median (interquartile range)

Alzheimer

13.60 (2)

Control

14.00 (1)

Alzheimer

114.00 (69)

Control

133.00 (96)

Alzheimer

26.00 (16)

Control

28.00 (19)

Alzheimer

52.00 (20)

Control

52.00 (25)

Z

P

–2.70

0.007*

–2.22

0.026µ

–1.73

0.084

–0.49

0.621

Mann–Whitney U test. *: P < 0.05, µ: P < 0.01.
500

168
o115
o

14
o
o9
o

Platelet count

400

300

200

100
Alzheimer

Group

Control

Figure 2. Comparison of intergroup platelet count by box plot
chart.

dL difference was statistically significant. Triglyceride value
was significantly different between the AD and control
groups (P < 0.05). LDL, very low-density lipoprotein
(VLDL), and HDL values were not significantly different
between the AD and control groups (P > 0.05).
The rates of diabetes and hypertension were not
statistically different between the AD and control groups
(P > 0.05) (Table 4).
Of the patients with AD, 31 (28.4%) had an MMSE
score below 18 and were placed in the ‘moderate’ group,
while 78 (71.6%) had an MMSE score of 18 or above and
were placed in the ‘mild’ group. The mean MMSE score of
patients in the moderate group was 13.26 ± 3.15, and it was
21.65 ± 3.02 in the mild group.
The value of MPV was not statistically significant
between the moderate group (<18) and the mild group
(≥18) in patients with AD (P > 0.05).

Table 4. Frequencies of diabetes and hypertension in groups.
Diabetes

Group

Yes

No

Alzheimer

31 (28.4%)

78 (71.6%)

Control

23 (24.7%)

58 (75.3%)

Total

54 (28.4%)

136 (71.6%)

χ2

P

0.00

1.000

1.48

0.224

Hypertension

Group

Yes

No

Alzheimer

72 (66.1%)

37 (33.9%)

Control

61 (75.3%)

20 (24.7%)

Total

133 (70%)

57 (30%)

Chi-square test.
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The values of total cholesterol, triglyceride, LDL,
VLDL, and HDL showing lipid profile were not statistically
significant between MMSE scores as grouped into a
moderate group (<18) and mild group (≥18) in patients
with AD (P > 0.05).
4. Discussion
In this study, we found that MPV was significantly higher
in patients with AD compared to controls.
MPV is a parameter showing platelet activation
and function. Although many methods are used for
demonstrating platelet reactivity, an easily accessible and
low-cost method is MPV measurement. There is a positive
correlation between MPV and increased platelet activity.
Platelets may differ in size and enzymatic activity in the
blood. Larger platelets are more active and they express
more GPIIb-IIIa and P-selectin, which are found on
platelets. These surface proteins’ roles in the platelets are
activation, aggregation, and endothelial adherence (22,23).
Aggregating platelets contribute to vasoconstriction and
lead to hypoperfusion of the brain. Reduced cerebral
blood was shown by transcranial Doppler ultrasound at an
early phase of AD by Claassen et al. (24). Thus, plateletmediated cerebral hypoperfusion can trigger pathology in
AD and cause neuronal energy deficiency.
AD is associated with the progressive deposition of Aβ
in the cerebral parenchyma and microvascular areas. Aβ, a
major component of amyloid plaques, originates from APP
via a proteolytic process. APP is also expressed in peripheral
tissues. Platelets are the most important peripheral source
of APP. APP and Aβ are stored in platelets and released
into circulation with platelet activation (2). The relation
between APP metabolism in platelets and AD is still
unclear. Platelets and neurons have numerous similar
features; both of them store and release neurotransmitters
and express similar proteins, such as NMDA receptors.
These features of platelets support their usefulness in
studying the pathogenetic process in AD (25). Yesil et al.
reported that increased MPV indicated a vascular risk
in AD. (26). Prodan et al. followed patients with AD for
2 years and reported a linear correlation between the
initial coated platelet levels and AD progression. They
evaluated the disease progression with repeated MMSE
administration (27). In our study, we evaluated the
relation between MPV and MMSE only at the first visit,
and we did not include patients who were diagnosed with
mild cognitive impairment (MCI). In addition, when the
patients with AD were divided into 2 subgroups, MPV
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was not statistically significantly different between the
moderate group (<18) and the mild group (≥18). Borroni
et al. reported that an abnormal pattern of APP in platelets
might contribute to endothelial damage through vascular
deposition of Aβ and trigger cerebrovascular pathology
in AD (2). Padovani et al. reported that patients with AD
had a reduced platelet/APP ratio (between the 130 kDa
and 106–110 kDa immunoreactivity bands with western
blot analysis) when compared with controls. In addition,
reduction of the platelet/APP ratio correlated with disease
severity (28). In this study, when the AD and control
groups are compared, it is seen that elevated MPV may be
an indicator of increased APP in platelets and also in the
brain, triggered by the same stimuli.
Several epidemiologic studies showed that vascular risk
factors such as hypertension, atherosclerosis, and diabetes
mellitus also play important roles in the progression
of AD (29,30). In our study, the rates of diabetes and
hypertension were not statistically different in the 2 groups,
but hemoglobin, haematocrit, and cholesterol values were
significantly higher in the controls. Elevated hemoglobin,
haematocrit, and cholesterol levels contribute to increased
blood viscosity. While the traditional view agrees that an
increased blood viscosity has a constantly negative impact
on tissue perfusion, and therefore should be considered as
a risk factor, some researchers argue that small increases
in viscosity actually have vasodilatory effects, potentially
improving tissue perfusion (31,32). In our study, lower
MPV levels in controls may indicate that there is less
vascular injury and better tissue perfusion.
There are several limitations of our study. First, patients
with MCI were not included in the study, and thus we
could not evaluate the relation between levels of MPV in
patients with MCI and AD. Second, platelet activity can
be influenced by multiple drugs. Although we excluded
patients who used antiplatelet drugs, different drugs (e.g.,
statins) other than platelet inhibitors also might influence
platelet functions and activity (33). In addition, assessment
of the relation between the APP ratio in platelets and MPV
might open new horizons for the role of MPV in AD
etiology.
In conclusion, increased MPV in patients with AD
may point to a platelet dysfunction. MPV is an indicator
of increased in vivo platelet activation. Hence, it can be
thought that platelets could be the link between the
vascular risk factors and AD. The assessment of MPV in
patients with AD may help identify the patients that could
benefit from additional antiplatelet therapy.
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